摘要
目的观察糖皮质激素不同给药方式治疗慢性阻塞性肺疾病急性加重期患者的疗效。方法选取2013年6月至2014年6月收治的慢性阻塞性肺疾病急性加重期患者58例,随机分为观察组(29例)和对照组(29例),分别给予口服甲泼尼龙片治疗和静脉滴注甲泼尼龙治疗,观察并比较两组疗效及并发症发生情况。结果治疗后,两组的氧分压(Pa O2)、第1秒用力呼气量(FEV1)、呼吸困难量表(MMRC)评分、慢性阻塞性肺疾病评估测试量表(CAT)评分较本组治疗前均出现显著改善(P<0.05),但两组间比较差异均无统计学意义(P>0.05)。对照组的并发症发生率为68.97%,显著高于观察组的10.34%(P<0.05)。结论口服和静脉滴注甲泼尼龙治疗慢性阻塞性肺疾病急性加重期患者,均能获得良好的治疗效果,但口服给药方式的并发症更少。
Objective To explore the effect of different administration modes of glucocorticoid for treating acute exacerbation of chronic obstructive pulmonary disease （ COPD ） . Methods 58 cases of acute exacerbation of COPD in our hospital from June 2013 to June 2014 were selected and randomly divided into the control group （ 29 cases ） and the observation group （ 29 cases ） . The two groups were treated by oral Methylprednisolone Tablets and intravenous methylprednisolone. The curative effects were observed and compared between the two groups. Results PaO2, FEV1, MMRC score and CAT score after treatment in the two groups were significantly improved com-pared with before treatment （ P〈 0. 05 ） . But PaO2, FEV1, MMRC scores and CAT scores in the two groups had no statistically signifi-cance differences between before and after treatment （ P 〉 0. 05 ） . The incidence rate of complications in the control group was 68. 97%, which was significantly higher than 10. 34% in observation group （ P〈 0. 05 ） . Conclusion Oral and intravenous methylpred-nisolone in the treatment of acute exacerbation of COPD all can obtain good therapeutic effect, but the oral administration mode has less complications.
出处
《中国药业》
CAS
2015年第9期47-48,共2页
China Pharmaceuticals
关键词
慢性阻塞性肺疾病
急性加重期
糖皮质激素
口服
静脉滴注
chronic obstructive pulmonary disease
acute exacerbation
glucocorticoid
administration mode
influence
